Actualités

If you are buying stocks with 10% yields, you have to make sure you appreciate the risks you are taking on.

Bitdeer’s adjusted EBITDA reached $31.1 million, while quarterly capital expenditures totaled $266 million as the operator expanded mining and AI infrastructure.

The cannabis stock has struggled despite Tilray achieving solid growth in its most recent fiscal year.

Investing.com -- Jefferies elevated Uber to a "Franchise Pick" and raised its price target on the stock to $110 from $100 per share in a note Monday, saying the setup for the ride-hailing and delivery company looks increasingly bullish following strong earnings and investor meetings.

(Updates with NABTU and BlackRock statements from press release in the last two paragraphs.) Blac

Fresh of its best week since April, the stock market took a breather Monday morning. The Dow Jones Industrial Average and S&P 500 were flat. The Nasdaq Composite was down 0.1%. WTI crude oil futures were up 1.

Archer Aviation holds an Olympic air taxi contract, a stack of blue-chip AI partnerships, and a clear FAA certification timeline, yet its shares sit closer to a 52-week low than a high. Something has to give, and the catalyst timeline is tighter than most investors realize.

Based on the average brokerage recommendation (ABR), IonQ (IONQ) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?

According to the average brokerage recommendation (ABR), one should invest in Cava (CAVA). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?

According to the average brokerage recommendation (ABR), one should invest in Baidu Inc. (BIDU). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?

Based on the average brokerage recommendation (ABR), Veeva (VEEV) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?

According to the average brokerage recommendation (ABR), one should invest in Palantir Technologies (PLTR). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?

According to the average brokerage recommendation (ABR), one should invest in Palo Alto (PANW). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?

The headline numbers for BITDEER TEC GRP (BTDR) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

The average brokerage recommendation (ABR) for Advanced Micro (AMD) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?

Based on the average brokerage recommendation (ABR), Marathon Petroleum (MPC) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?

Based on the average brokerage recommendation (ABR), JPMorgan Chase & Co. (JPM) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?

Barrick Mining has settled a long-standing dispute with rival Newmont over their Nevada operations, securing a $1.95 billion cash payout and paving the way for Barrick to publicly list its North American gold assets.

American Airlines Group Inc. (NASDAQ:AAL) delivered a record second quarter, with revenue climbing 16.3% year over year to an all-time high of $16.7 billion as demand strengthened across premium, corporate, domestic, and international travel. Adjusted earnings of $0.15 per diluted share also topped Wall Street expectations. However, an 83% surge in fuel expense largely offset […]

RVLV's active customers rise 11% to 3.04 million as record additions, stronger engagement and investments in brand building, AI and shopping experience drive growth.

Treasury yields rise ahead of U.S. inflation data due later this week and following July's unexpected negative payroll numbers. Iran makes tough demands to reopen Hormuz, pushing oil futures up 1.5%. Economists surveyed by WSJ expect July's 12-month CPI inflation to cool slightly to 3.

Apple is seeking White House approval to use chips from CXMT in devices sold in China amid an AI-driven component shortage

Retailers in the United States are a bit mixed in early Monday trading.

Nuclear fuel supplier Centrus Energy (NYSE:LEU) reported Q2 CY2026 results beating Wall Street’s revenue expectations, with sales up 14% year on year to $176.1 million. Its non-GAAP profit of $0.77 per share was 4.9% below analysts’ consensus estimates.

SIMO's revenue surged 127% in Q2, while embedded, enterprise and AI storage ramps support its strong Q3 growth outlook.

Serial cryptocurrency acquirer Strategy (NASDAQ: $MSTR) continued to sell both Bitcoin (CRYPTO: $BTC) and its commo...

The miner liquidated 23,093 bitcoin during the first half, shifting its treasury from passive holdings toward debt reduction and capital for AI infrastructure.

Rivian's R2 ramp and software gains support growth, but heavy cash burn, execution risks and elevated capital needs keep the stock a Hold.

INOD's AI-driven growth accelerates as strong Q2 results, customer diversification and new solutions strengthen its long-term potential.

Vertex stock surged Monday after its competitor, Sionna Therapeutics, missed the mark for its highly anticipated cystic fibrosis treatment.